Clinical trials using anti-CD39 mAbs TTX-030 (NCT04306900, NCT06119217) and ES002023 (NCT05075564) in cancer therapy are ongoing (www.clinicaltrials.gov). The gene discussed is ENTPD1; the disease is cancer.